Clinical Trials Sponsored by Sichuan Jishengtang Pharmaceutical Co., Ltd.

Total 3863 results

Peking University
Sichuan Jishengtang Pharmaceutical Co., Ltd.

Not yet recruiting

A Multicenter Clinical Study on Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression

Outpatients / Inpatients With Depression

China
Sichuan Jishengtang Pharmaceutical Co., Ltd.

Not yet recruiting

Randomized Clinical Trial of Shugan Jieyu Capsule in Generalized Anxiety Disorder

Generalized Anxiety Disorder
Sichuan Huiyu Pharmaceutical Co., Ltd

Recruiting

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Efficacy | Tolerability | Safety

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors

Her2-positive/Low-expression Urinary and Digestive Tract Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Non-nasopharyngeal Carcinoma) and Other Solid Tumors

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Relapsed/Refractory Chronic Lymphocytic Leukemia

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Squamous Cell Carcinoma of Lung | Non-small Cell Lung Adenocarcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Esophageal Squamous Cell Carcinomas

China
Sichuan Baili Pharmaceutical Co., Ltd.

Terminated

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Colorectal Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Unknown

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Ventricular Fibrillation | Ventricular Tachycardia

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Gastric Cancer | Colorectal Cancer | Esophageal Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Solid Tumor | Urothelial Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

Clinical Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Non Small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Sichuan University
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | ALK Fusion Protein Expression | Adjuvant Therapy
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Nasopharyngeal Carcinoma | Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Solid Tumor | Gynecological Malignant Tumor

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Withdrawn

A Study Evaluating the Mass Balance of Micro-dose[14C]HSK3486 Emulsion Injection in Healthy Adults

Anesthesia | Sedation
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

Sedation

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of HSK21542 in Healthy Volunteers

Chronic Pain | Postoperative Pain

Australia
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

Acute Drug Induced Liver Injury

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study on the Bioequivalence of Perindopril Tert-butylamine Tablets Taken on After Meals in Healthy Subjects

Healthy

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Single IV Dose of HSK3486 Injectable Emulsion in Healthy Subjects.

Anesthesia | Sedation
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion for the Induction of General Anesthesia in Elective Surgery Subjects

Induction of Anesthesia

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion in Patients

Colonoscopy

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Efficacy and Safety of HSK3486

Sedation and Anesthesia for Adult Colonoscopy Procedures

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Locally Advanced or Metastatic Solid Tumors

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer

HR+HER2- Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

HER2-positive Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies

Gynecological Malignancies

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Cervical Cancer

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Diabetes Mellitus, Type 2

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of HSK3486 Single Bolus Dose Followed With a 30 Minute Constant Infusion in Healthy Male Subjects

Anesthesia | Sedation
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Voriconazole Tablets

Anesthesia | Sedation

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Clinical Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Elective Surgery Patients

Induction and Maintenance of General Anesthesia

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Trial Evaluating the Efficacy and Safety of HSK3486 Injectable Emulsion in Subjects Undergoing Fiberoptic Bronchoscopy

Sedation or Anesthesia

China
Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

A Study Evaluating the Safety and Pharmacokinetics/Pharmacodynamics of HSK3486

Anesthesia | Sedation

China

3

Subscribe